<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67682">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224742</url>
  </required_header>
  <id_info>
    <org_study_id>12EN005</org_study_id>
    <secondary_id>ISRCTN27665670</secondary_id>
    <nct_id>NCT02224742</nct_id>
  </id_info>
  <brief_title>LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers</brief_title>
  <official_title>LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nottingham University Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic foot ulcers are the source of considerable suffering and cost and there are
      currently no wound care products available that have been demonstrated to improve healing,
      or that are cost effective. There have however been a small number of studies which have
      examined the use of platelets or fluid derived from platelets, either from the patient's own
      blood or from blood bank products. These have suggested some promise, but have suffered from
      technical difficulties in making a suitable wound care product or the volume of blood
      required to derive the product. It is thought that the reason why they may work is that
      growth factors released by the platelets may stimulate the wound to heal.

      This study will be a formal, randomised controlled trial to assess a new device for creating
      a wound care product which is a plug or patch comprising fibrin, white cells and platelets
      derived from 18 mls of the patients own blood. The application of this fibrin/white
      cell/platelet patch to the patients wound on a weekly basis will be compared with usual best
      care in patients with hard to heal Diabetic Foot Ulcers in a secondary care setting in 25
      centres in the United Kingdom, Denmark and Sweden.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing</measure>
    <time_frame>Within 20 weeks of randomisation</time_frame>
    <description>Healing will be defined as complete epithelialisation without discharge that is maintained for 4 weeks and is confirmed by an observer blind to randomisation group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>LeucoPatch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Usual care supplemented by the application of LeucoPatch centrifugates that comprise autologous fibrin patches containing living white cells and platelets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care provided in a multidisciplinary foot care clinic, in accordance with international guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LeucoPatch</intervention_name>
    <description>LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.</description>
    <arm_group_label>LeucoPatch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.
Components of usual wound care include:
Formal assessment of ulcer and surrounding skin
Provision of any necessary off-loading
Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)
Appropriate dressing products
Appropriate antibiotic therapy
Nutrition and self care
Optimal glycaemic control
Revascularisation if deemed clinically necessary
Continued close observation</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  People aged 18 years and over who have diabetes complicated by one or more ulcers on
             a foot or both feet below the level of the malleoli, excluding ulcers confined to the
             interdigital cleft.

          -  Those with more than one eligible ulcer will have one - usually the largest or more
             clinically significant - selected at screening as the index ulcer.

          -  Eligible ulcers will be hard-to-heal, meaning that the cross-sectional area will
             decrease by less than 50 % during a four week run-in period.

          -  HbA1c ≤108 mmol/mol at screening

          -  The cross-sectional area of the index ulcer will be ≥50 and ≤1000 mm2 at the end of
             the 4 week run-in period.

          -  The index ulcer will be clinically non-infected according to IDSA criteria

          -  Either the ankle-brachial index (ABPI) in the affected limb will be between 0.50 and
             1.40 or the dorsalis pedis pulse and/or tibialis posterior pulse will be palpable.

          -  Participants will have the capacity to understand study procedures, and will be able
             to provided written informed consent.

        Exclusion Criteria:

          -  Haemoglobin concentration &lt;105 g/L or 6.5 mmol/L at screening.

          -  Presence of sickle-cell anaemia, haemophilia, thrombocytopenia (&lt;100x109/L) or other
             clinically significant blood dyscrasia

          -  Known potential infectivity of blood products, including known HIV and hepatitis

          -  Dialysis or an estimated GFR (based on cystatine C or serum creatinine) &lt;20
             ml/min/1.73m2

          -  Increase in cross-sectional area of the index ulcer by ≥25% during the 4 week run-in
             period, or is either smaller than 50 mm2 or larger than 1000 mm2 at the end of that
             time

          -  Revascularisation procedure in the affected limb planned, or undertaken within the 4
             weeks prior to screening

          -  Current treatment with cytotoxic drugs or with systemically administered
             glucocorticoids

          -  Treatment of foot ulcers with growth factors, stem cells or equivalent preparation
             within the 8 weeks prior to screening

          -  Likely inability to comply with the need for weekly visits because of planned
             activity

          -  Participation in another interventional clinical foot ulcer-healing trial within the
             4 weeks prior to screening

          -  Prior enrollment in this trial

          -  Judgement by the investigator that the patient does not have the capacity to
             understand the study procedures or provide written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances Game, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Derby Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence Day, BSc, MA</last_name>
    <phone>0115 8844933</phone>
    <email>florence.day@nottingham.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Rossing, MD</last_name>
      <email>pro@steno.dk</email>
    </contact>
    <investigator>
      <last_name>Peter Rossing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Michelsen, MD</last_name>
      <email>moismi02@heh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Morten Michelsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Sørensen, MD</last_name>
      <email>j.soerensen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Jan Sørensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Kobenhavn NV</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Jørgensen, MMSc</last_name>
      <email>Bj05@bbh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Bo Jørgensen, MMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kolding Sygehus</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Houlind, MMSc, PhD</last_name>
      <email>kim.christian.houlind@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Kim Houlind, MMSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Marie Nielsen, MD</last_name>
      <email>anna.marie.nielsen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Anna Marie Nielsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Viborg Sårcenter</name>
      <address>
        <city>Viborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eskild Henneberg, MD</last_name>
      <email>eskild.w.henneberg@viborg.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Eskild Henneberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Löndahl, MD, PhD</last_name>
      <email>magnus.londahl@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Magnus Löndahl, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospitals NHS Trust</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TRI 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harvey Chant, FRCS</last_name>
      <email>Harvey.Chant@rcht.cornwall.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Harvey Chant, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Devon Healthcare NHS Foundation Trust</name>
      <address>
        <city>Torquay</city>
        <state>Devon</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghislaine Spyer, MRCP, MD</last_name>
      <email>gspyer@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Ghislaine Spyer, MRCP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ipswich Hospital NHS Trust</name>
      <address>
        <city>Ipswich</city>
        <state>Suffolk</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerrard Rayman, FRCP</last_name>
      <email>gerry.rayman@ipswichhospital.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Gerrard Rayman, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mid Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Pontefract</city>
        <state>West Yorkshire</state>
        <zip>WF8 1PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan D'Costa, FRCP</last_name>
      <email>ryan.dcosta@midyorks.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ryan D'Costa, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Whitelaw, FRCP</last_name>
      <email>Donald.Whitelaw@bthft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Donald Whitelaw, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derby Hospitals NHS Foundation Trust</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Game, FRCP</last_name>
      <email>frances.game@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Frances Game</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>United Lincolnshire Hospitals NHS Trust</name>
      <address>
        <city>Lincoln</city>
        <zip>LN2 5QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajagopalan Sriraman, MRCP, PhD</last_name>
      <email>Rajagopalan.Sriraman@ULH.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rajagopalan Sriraman, MRCP, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norwich and Norwich University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ketan Dhatariya, FRCP</last_name>
      <email>ketan.dhatariya@nnuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ketan Dhatariya, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Jeffcoate, FRCP</last_name>
      <email>william.jeffcoate@gmail.com</email>
    </contact>
    <investigator>
      <last_name>William Jeffcoate, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Hospitals Sunderland NHS Foundation Trust</name>
      <address>
        <city>Sunderland</city>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahul Nayar, FRCP</last_name>
      <email>Rahul.Nayar@chsft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rahul Nayar, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Wolverhampton Hospitals NHS Trust</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Oguntolu, MRCP, MSc</last_name>
      <email>victor.oguntolu@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Victor Oguntolu, MRCP, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 21, 2016</lastchanged_date>
  <firstreceived_date>August 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
